Ramsay Sante : Q1 results as of September 30, 2024
PRESS RELEASE
PRESS RELEASE
Paris,
7th November 2024
Q1 results as of September 30,
2024
Unaudited group revenue increased by 8.6%
to €1.18bn supported by price increases and volume growth in France
and Sweden reflecting sustained patient need for healthcare and the
capacity of the group’s facilities to provide more care services
despite staffing challenges from competition for nurses in Europe.
Revenue growth on a like-for-like basis was 5.9%.
Unaudited group EBITDA increased by 15.1%
over the quarter ending September 2024 compared to previous year
corresponding period, to €105.4m with an EBITDA margin of 9.0% for
the quarter (vs 8.5% in the prior corresponding period). Results
for the first 3 months of our French MSO activities include the
positive tariff impact from the cancellation of the CICE
coefficient since 1st July 2024 (benefit from the full impact of
tax credit for competitiveness and employment) adding the
equivalent of a +2,2% tariff increase to the initial French MSO
tariffs. This represents only a partial catch-up on prior years
inflation which is still under-funded by governments. In this
context, Ramsay Santé has reinforced its cost base restructuring
efforts and productivity improvements.
Net financial debt as of 30 September
2024 amounted to €3,777m, including €1,952m of IAS17 (pre-IFRS16)
debt. Pre-IFRS16 unaudited net leverage amounts to 5.3x as of
September 2024, stable vs. September 2023.
Significant milestones were achieved over
the last quarter in the implementation of our “Yes We Care 2025”
strategy confirming Ramsay Santé as a provider of choice to our
stakeholders to cover the entire patient journey:
- On
22nd October 2024,
Capio was awarded the assignment to provide care at St. Göran's
Hospital in Stockholm for eight additional years from January 2026,
with the right for Region Stockholm to extend the agreement further
by up to four years, for a contract value, calculated for twelve
years, of approx. €4,8bn (SEK 55 billion).
- In June 2024, the group
took over 12 existing Cosem primary care centres in Paris and other
major French cities, handling more than 1 million patient
consultations per annum. The integration process within Ramsay
Santé has been initiated over the summer and takes place under good
conditions.
- On
13th August 2024,
Ramsay Santé successfully refinanced its €1,650m senior debt
facilities with an Amend & Extend agreement, proactively
extending its upcoming 2026-2027 debt maturities to 2029-2031,
hence providing to all its stakeholders a long-term financing
framework to support medical excellence as well as the
implementation of its key initiatives of the “Yes We Care 2025”
strategic plan.
Activity and revenue:
Ramsay Santé Group reported a consolidated
revenue of €1,176m for the quarter ended 30 September 2024, up 8.6%
on a reported basis. Adjusted for changes in the consolidation
scope and at constant currency exchange rates, revenue for the
first quarter was up with a solid 5.9% organic sales growth.
France revenue has grown by 9.7% including the
contribution of the 12 Cosem primary care centers taken over by
Ramsay Santé in June 2024 and supported by (i) an increase in
volumes supported by 2 additional business days this quarter
compared to last year (ii) higher revenues from rechargeable
medical purchases as well as (iii) price increase from the
cancellation of the CICE coefficient from 1st July 2024 (benefit
from the full impact of tax credit for competitiveness and
employment) adding the equivalent of a +2.2% tariff increase to the
initial +0.3% MSO tariff increase from March 2024. France total
admissions in our hospitals rose vs. prior corresponding period
extending and confirming the contribution of the group’s facilities
to address the post-Covid backlog of elective hospital care: +4.0%
in MSO (medicine, surgery and obstetrics) and +11.4% in mental
health. Our French facilities managed approximately 172,000
emergency presentations this quarter, similar to last year,
confirming their important role in delivering on public service
missions. Chemotherapy sessions increased by +7.1%, and dialysis
sessions by +0.9% vs Q1 2023.
Nordic countries reported revenue grew by +6.1%
benefiting from €9.5m (or +2.8%) favourable foreign exchange rate
fluctuations (appreciation of SEK/NOK vs EUR on average vs last
year). Organic revenue growth in the Nordic countries for the
quarter ending 30 September 2024 was +3.0% on a like-for-like basis
and at constant exchange rate, despite the loss of some primary
care contracts.
EBITDA:
EBITDA reached €105.4m for the three-month
period ending 30 September 2024, up €13.8m or 15.1% on the prior
corresponding period. The Group's EBITDA as at 30 September 2024
includes €7.2m (last year €14.0m) of French government's revenue
guarantee, having a reduced contribution from its lower coverage
mechanism and the increasing activity in the facilities still
benefitting from the scheme. EBITDA and margins continue to be
impacted by inflationary pressures from medical staff salary and
wages as well as overall procurement and outsourced services price
increases. Ramsay Santé received funding through French tariff
increases and Nordics agreements indexation with various public
payors which only partially covered procurement and wages
inflation. Cost control measures were sustained to adapt activities
to current inflation environment and resources allocation are
revisited as a consequence.
Reported EBITDA of €105.4m for the first quarter
ending 30 September 2024 (vs. €91.6m last year) in accordance with
IFRS16 excludes contracted lease expenses for €66.2m (vs. €59.8m
last year) which are instead recorded as amortisation of the
right-of-use asset and interest on the lease debt. The increase in
the lease accounting impact vs. prior year primarily came from the
effect of price indexation mechanism and the contribution of FY24
acquisitions (e.g. COSEM).
Cash flow &
financing
Net cash flow from operating activities of
€(31.0)m reflects the lower seasonality of our medical, surgical
and obstetrical activities over the summer months, and its decrease
versus €(8.5)m in the prior corresponding period primarily arises
from the negative working capital variation linked to the repayment
of French government cash advances over the summer. These were
extended in April and May to compensate the billing hold caused by
the late publication of 2024 tariffs.
Net financial debt as of 30 September 2024
amounted to €3,777m, including €1,952m of IAS17 (pre-IFRS16) debt.
Pre-IFRS16 unaudited net leverage amounts to 5.3x at the end of
September 2024, stable vs. September 2023.
Pascal Roché, CEO of Ramsay Santé
says:
“I would like to congratulate the team at St
Göran on the recent extension of the contract to operate this major
pluri-disciplinary public hospital serving the population of
Stockholm and beyond. It is a testament to the quality of the care
they provide to patients every day, earning a well-deserved
recognition of their contribution to the provision of healthcare
services to the public, from emergency, scheduled care, maternity,
to oncology. I also warmly welcome the primary care teams joining
us in the former COSEM medical centres, which provide almost 10% of
medical consultations in Paris. I am confident about the
opportunities for collaboration and coordination of care pathways
that will result with our facilities located near these centres in
Paris, but also in Marseille, St Etienne, Orleans and Caen. Whilst
in the midst of challenging budgetary constraints, these positive
developments of the care we offer to all patients is an integral
part of our mission and confirms our Yes We Care 2025 strategy,
towards a more inclusive and integrated healthcare delivery system,
covering the entire care pathway of patients.”
In the context of its new debt financing
agreement, Ramsay Santé releases this unaudited first quarter
trading update as of September 2024, this release having been
approved by the Board of Directors at its meeting held on
7th November 2024.
About Ramsay Santé
Ramsay Santé is the leader in private
hospitalisation and primary care in Europe. The Group has 38,000
employees and works with nearly 9,300 practitioners to treat more
than 12 million patients per year in its 465 facilities and 5
countries: France, Sweden, Norway, Denmark and Italy. Ramsay Santé
offers almost all medical and surgical specialities in three
domains: Medicine, Surgery, Obstetrics (MSO), Follow-up Care and
Rehabilitation (FCR) and Mental Health.
Legally, Ramsay Santé is a mission-driven company committed to
constantly improving the health of all patients through innovation.
Wherever it operates, the Group contributes to public health
service missions and the healthcare network. Through its actions
and the constant dedication of its teams, Ramsay Santé is committed
to ensuring the entire patient care journey, from prevention to
follow-up care.
Every year, the group invests over 200 million euros to support the
evolution and diversity of care pathways, in medical, hospital,
digital, and administrative aspects. Through this commitment, our
Group enhances access to care for all, commits to provide
best-in-class healthcare, systematically engages in dialogue with
stakeholders and strives to protect the planet to improve
health.
Facebook: https://www.facebook.com/RamsaySante
Instagram: https://www.instagram.com/ramsaysante
Twitter: https://twitter.com/RamsaySante
LinkedIn: https://www.linkedin.com/company/ramsaysante
YouTube: https://www.youtube.com/c/RamsaySante
Code ISIN and Euronext Paris:
FR0000044471
Website:
www.ramsaysante.fr
Investor / Analyst
Relations Press
Relations
Clément
Lafaix Brigitte
Cachon
Tél. +33 1 87 86 21
52 Tél. +33 1 87 86
22 11
clement.lafaix@ramsaysante.fr brigitte.cachon@ramsaysante.fr
Summary of unaudited quarterly
results
Changes in reported revenues
Reported revenue Q1 23 |
Changes in FX rates |
Acquisitions and disposals |
Organic growth |
Reported revenue Q1 24 |
Variation |
1,083.0 |
9.5 |
19.1 |
64.1 |
1,175.7 |
92.7 |
|
0.9% |
1.8% |
5.9% |
|
+8.6% |
EBITDA reconciliation – in € millions |
From July 1, 2024 to September 30, 2024 |
From July 1, 2023 to September 30, 2023 |
Variation |
Reported EBITDA |
105.4 |
91.6 |
+15.1% |
IFRS16 impact |
66.2 |
59.8 |
+10.7% |
EBITDA pre-IFRS16 |
39.2 |
31.8 |
+23.3% |
Note: IFRS16 impact on operating lease only.
EBITDA pre-IFRS16 is already restated from financial
leases.
Net Financial Debt – in € millions |
September 30, 2024 |
June 30, 2024 |
Non-current borrowings and debt |
1,851.8 |
1,880.0 |
Non-current lease debt |
1,775.9 |
1,800.7 |
Current lease debt |
246.9 |
245.1 |
Current borrowings and debt |
56.5 |
104.3 |
(Cash and cash equivalents) |
(109.7) |
(359.0) |
Other financial (assets) & liabilities |
(44.4) |
(60.2) |
Net financial debt |
3,777.0 |
3,610.9 |
Cash Flow Statement – in € millions |
From July 1, 2024 to September 30, 2024 |
From July 1, 2023 to September 30, 2023 |
EBITDA (a) |
105.4 |
91.6 |
Changes in working capital (b) |
(123.6) |
(91.0) |
Other items (c) |
(12.8) |
(9.1) |
Net cash flow from operating activities
(a)+(b)+(c) |
(31.0) |
(8.5) |
Net cash flow from investing activities |
(33.4) |
(48.4) |
Net cash flow from financing activities |
(186.1) |
(103.6) |
Change in net cash position |
(250.5) |
(160.5) |
FX translation differences on cash and cash
equivalents |
1.2 |
1.8 |
Opening cash and cash equivalents |
359.0 |
352.2 |
Closing cash and cash equivalents |
109.7 |
193.5 |
- Ramsay Santé - Quaterly Results as of 30.09.2024
Ramsay Generale De Sante (EU:GDS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Ramsay Generale De Sante (EU:GDS)
Historical Stock Chart
From Dec 2023 to Dec 2024